Branded Prescription Drug Fee

The IRS has issued Notice 2012-74, which provides guidance on the ACA branded prescription drug (BPD) fee for the 2013 fee year. Specifically, the guidance addresses: (1) the submission of Form 8947, “Report of Branded Prescription Drug Information,” (2) the time and manner for notifying covered entities of their preliminary fee calculation, (3) the

The Internal Revenue Service (IRS) is holding a November 9, 2012 public hearing on the ACA’s branded prescription drug fee.  The subject of the hearing will be the agency’s August 18, 2011 notice of proposed rulemaking that cross-referenced temporary regulations also issued on August 18.  The IRS must receive outlines of topics to be discussed at

This post was also written by Ruth Holzman.

The IRS has issued updated guidance to drug manufacturers on the Affordable Care Act’s annual fee imposed on covered entities engaged in the business of manufacturing or importing branded prescription drugs. The guidance addresses submission of required information, IRS notification of covered entities of their